Chinese General Practice ›› 2023, Vol. 26 ›› Issue (24): 2980-2985.DOI: 10.12114/j.issn.1007-9572.2022.0794
• Original Research • Previous Articles Next Articles
Received:
2022-11-16
Revised:
2022-12-30
Published:
2023-08-20
Online:
2023-02-02
Contact:
CHENG Gong
通讯作者:
程功
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0794
组别 | 例数 | 年龄( | BMI ( | 男/女 | 吸烟史〔例(%)〕 | 入院时血压情况( | 病史〔例(%)〕 | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
收缩压 | 舒张压 | 脉压差 | 高血压 | 高血脂 | 糖尿病 | 慢性阻塞性肺疾病史 | 甲状腺疾病 | ||||||
非钙化组 | 73 | 57.6±10.1 | 24.6±2.5 | 61/12 | 34(46.6) | 127±16 | 78±11 | 49±14 | 29(39.7) | 12(16.4) | 15(20.5) | 6 (8.2) | 2 (2.7) |
低钙化指数组 | 62 | 60.7± 9.8 | 24.4±2.7 | 52/10 | 26(41.9) | 134±18 | 80±12 | 52±16 | 32(51.6) | 16(25.8) | 28(45.2)a | 9(14.5) | 3 (4.8) |
高钙化指数组 | 61 | 65.3±8.8ab | 24.5±3.0 | 40/21ab | 16(26.2)a | 132±16 | 78±10 | 54±11 | 39(63.9)a | 8(13.1) | 25(41.0)b | 5 (8.2) | 7(11.5)a |
F(χ2)值 | 10.779 | 0.069 | 8.066c | 6.176 | 2.430 | 1.093 | 1.994 | 7.806c | 3.592c | 10.511c | 1.840c | 4.672c | |
P值 | <0.001 | 0.934 | 0.018 | 0.046 | 0.091 | 0.337 | 0.139 | 0.020 | 0.166 | 0.005 | 0.398 | 0.039 |
Table 1 Comparison of general information among the non-calcification group,low-calcification index group and high-calcification index group
组别 | 例数 | 年龄( | BMI ( | 男/女 | 吸烟史〔例(%)〕 | 入院时血压情况( | 病史〔例(%)〕 | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
收缩压 | 舒张压 | 脉压差 | 高血压 | 高血脂 | 糖尿病 | 慢性阻塞性肺疾病史 | 甲状腺疾病 | ||||||
非钙化组 | 73 | 57.6±10.1 | 24.6±2.5 | 61/12 | 34(46.6) | 127±16 | 78±11 | 49±14 | 29(39.7) | 12(16.4) | 15(20.5) | 6 (8.2) | 2 (2.7) |
低钙化指数组 | 62 | 60.7± 9.8 | 24.4±2.7 | 52/10 | 26(41.9) | 134±18 | 80±12 | 52±16 | 32(51.6) | 16(25.8) | 28(45.2)a | 9(14.5) | 3 (4.8) |
高钙化指数组 | 61 | 65.3±8.8ab | 24.5±3.0 | 40/21ab | 16(26.2)a | 132±16 | 78±10 | 54±11 | 39(63.9)a | 8(13.1) | 25(41.0)b | 5 (8.2) | 7(11.5)a |
F(χ2)值 | 10.779 | 0.069 | 8.066c | 6.176 | 2.430 | 1.093 | 1.994 | 7.806c | 3.592c | 10.511c | 1.840c | 4.672c | |
P值 | <0.001 | 0.934 | 0.018 | 0.046 | 0.091 | 0.337 | 0.139 | 0.020 | 0.166 | 0.005 | 0.398 | 0.039 |
组别 | 例数 | WBC ( | RBC ( | NLR 〔M(P25,P75)〕 | HB ( | PLT ( | TP ( | ALB 〔M(P25,P75),g/L〕 |
---|---|---|---|---|---|---|---|---|
非钙化组 | 73 | 7.28±2.39 | 4.45±0.51 | 2.56(1.87,3.24) | 139.00±17.00 | 203.00±52.00 | 62.80±5.24 | 37.00(35.00,40.00) |
低钙化指数组 | 62 | 7.35±2.21 | 4.48±0.62 | 2.62(1.96,3.87) | 138.00±20.00 | 213.00±58.00 | 65.07±6.77a | 38.40(35.70,40.90) |
高钙化指数组 | 61 | 7.26±2.28 | 4.36±0.55 | 2.89(1.89,4.31) | 133.00±17.00 | 207.00±55.00 | 66.42±7.48a | 37.8(35.3,40.6) |
F(Z)值 | 0.240 | 0.847 | 0.974c | 1.828 | 0.370 | 5.338 | 0.676c | |
P值 | 0.975 | 0.424 | 0.299 | 0.162 | 0.583 | 0.006 | 0.596 | |
组别 | A/G 〔M(P25,P75)〕 | ALT 〔M(P25,P75),U/L〕 | AST 〔M(P25,P75),U/L〕 | ALP ( | GGT 〔M(P25,P75),U/L〕 | TBiL〔M(P25,P75),μmol/L〕 | DBiL〔M(P25,P75),μmol/L〕 | |
非钙化组 | 1.45(1.22,1.69) | 21.00(14.00,35.00) | 21.00(18.00,28.00) | 61.38±18.45 | 23.00(16.00,31.00) | 12.12(9.52,16.23) | 4.61(3.87,6.53) | |
低钙化指数组 | 1.48(1.30,1.60) | 23.00(15.00,33.00) | 21.00(17.00,44.00) | 86.69±28.45a | 29.00(20.00,43.00)a | 12.61(9.20,17.31) | 4.65(3.81,4.42) | |
高钙化指数组 | 1.32(1.19,1.51)ab | 20.00(16.00,31.00) | 24.00(18.00,47.00) | 80.25±18.76a | 24.00(18.00,32.00)b | 12.32(9.31,17.50) | 4.46(3.54,6.51) | |
F(Z)值 | 1.433c | 0.763c | 0.880c | 24.055 | 0.612c | 0.734c | 0.706c | |
P值 | 0.014 | 0.614 | 0.465 | <0.001 | 0.039 | 0.805 | 0.852 | |
组别 | TC ( | TG 〔M(P25,P75),μmol/L〕 | HDL-C ( | LDL-C ( | UA ( | UREA ( | CRE ( | |
非钙化组 | 3.74±0.96 | 1.19(0.99,1.55) | 0.94±0.22 | 2.27±0.81 | 316.34±88.75 | 5.52±1.58 | 66.04±16.2 | |
低钙化指数组 | 3.93±1.08 | 1.55(1.24,2.04)a | 0.94±0.18 | 2.46±0.91 | 332.29±106.74 | 5.52±1.96 | 66.62±28.4 | |
高钙化指数组 | 3.95±0.94 | 1.44(1.17,1.91)a | 0.96±0.22 | 2.25±0.79 | 327.43± 78.42 | 6.05±2.37 | 67.84±28.4 | |
F(Z)值 | 0.921 | 2.000c | 5.280 | 1.127 | 0.540 | 1.552 | 0.092 | |
P值 | 0.400 | <0.001 | 0.543 | 0.326 | 0.584 | 0.214 | 0.913 | |
组别 | Ca〔M(P25,P75),μmol/L〕 | P〔M(P25,P75),μmol/L〕 | K〔M(P25,P75),μmol/L〕 | GLU〔M(P25,P75),μmol/L〕 | HbA1c〔M(P25,P75),g/L〕 | TyG Index〔M(P25,P75),mg/dL〕 | Fg 〔M(P25,P75),g/L〕 | |
非钙化组 | 2.26 (2.2,2.37) | 1.06(0.98,1.22) | 4.00(3.85,4.30) | 6.01(5.11,7.32) | 5.92(5.61,6.32) | 3.75(2.83,4.78) | 3.02(2.66,3.53) | |
低钙化指数组 | 2.28(2.22,2.39) | 1.13(0.98,1.28) | 4.10(3.80,4.40) | 6.42(5.13,8.14) | 6.32(5.91,7.41)a | 5.28(3.59,7.15)a | 2.91(2.62,3.61) | |
高钙化指数组 | 2.29(2.21,2.39) | 1.19(1.07,1.31)a | 4.01(3.71,4.32) | 6.61(5.22,8.51) | 6.22(5.91,7.52)a | 5.36(3.57,7.59)a | 3.11(2.56,3.61) | |
F(Z)值 | 0.513c | 1.772c | 0.659c | 1.256c | 1.114c | 2.216c | 0.704c | |
P值 | 0.577 | 0.005 | 0.357 | 0.520 | 0.012 | <0.001 | 0.948 |
Table 2 Comparison of laboratory findings among the non-calcification group,low-calcification index group and high-calcification index group
组别 | 例数 | WBC ( | RBC ( | NLR 〔M(P25,P75)〕 | HB ( | PLT ( | TP ( | ALB 〔M(P25,P75),g/L〕 |
---|---|---|---|---|---|---|---|---|
非钙化组 | 73 | 7.28±2.39 | 4.45±0.51 | 2.56(1.87,3.24) | 139.00±17.00 | 203.00±52.00 | 62.80±5.24 | 37.00(35.00,40.00) |
低钙化指数组 | 62 | 7.35±2.21 | 4.48±0.62 | 2.62(1.96,3.87) | 138.00±20.00 | 213.00±58.00 | 65.07±6.77a | 38.40(35.70,40.90) |
高钙化指数组 | 61 | 7.26±2.28 | 4.36±0.55 | 2.89(1.89,4.31) | 133.00±17.00 | 207.00±55.00 | 66.42±7.48a | 37.8(35.3,40.6) |
F(Z)值 | 0.240 | 0.847 | 0.974c | 1.828 | 0.370 | 5.338 | 0.676c | |
P值 | 0.975 | 0.424 | 0.299 | 0.162 | 0.583 | 0.006 | 0.596 | |
组别 | A/G 〔M(P25,P75)〕 | ALT 〔M(P25,P75),U/L〕 | AST 〔M(P25,P75),U/L〕 | ALP ( | GGT 〔M(P25,P75),U/L〕 | TBiL〔M(P25,P75),μmol/L〕 | DBiL〔M(P25,P75),μmol/L〕 | |
非钙化组 | 1.45(1.22,1.69) | 21.00(14.00,35.00) | 21.00(18.00,28.00) | 61.38±18.45 | 23.00(16.00,31.00) | 12.12(9.52,16.23) | 4.61(3.87,6.53) | |
低钙化指数组 | 1.48(1.30,1.60) | 23.00(15.00,33.00) | 21.00(17.00,44.00) | 86.69±28.45a | 29.00(20.00,43.00)a | 12.61(9.20,17.31) | 4.65(3.81,4.42) | |
高钙化指数组 | 1.32(1.19,1.51)ab | 20.00(16.00,31.00) | 24.00(18.00,47.00) | 80.25±18.76a | 24.00(18.00,32.00)b | 12.32(9.31,17.50) | 4.46(3.54,6.51) | |
F(Z)值 | 1.433c | 0.763c | 0.880c | 24.055 | 0.612c | 0.734c | 0.706c | |
P值 | 0.014 | 0.614 | 0.465 | <0.001 | 0.039 | 0.805 | 0.852 | |
组别 | TC ( | TG 〔M(P25,P75),μmol/L〕 | HDL-C ( | LDL-C ( | UA ( | UREA ( | CRE ( | |
非钙化组 | 3.74±0.96 | 1.19(0.99,1.55) | 0.94±0.22 | 2.27±0.81 | 316.34±88.75 | 5.52±1.58 | 66.04±16.2 | |
低钙化指数组 | 3.93±1.08 | 1.55(1.24,2.04)a | 0.94±0.18 | 2.46±0.91 | 332.29±106.74 | 5.52±1.96 | 66.62±28.4 | |
高钙化指数组 | 3.95±0.94 | 1.44(1.17,1.91)a | 0.96±0.22 | 2.25±0.79 | 327.43± 78.42 | 6.05±2.37 | 67.84±28.4 | |
F(Z)值 | 0.921 | 2.000c | 5.280 | 1.127 | 0.540 | 1.552 | 0.092 | |
P值 | 0.400 | <0.001 | 0.543 | 0.326 | 0.584 | 0.214 | 0.913 | |
组别 | Ca〔M(P25,P75),μmol/L〕 | P〔M(P25,P75),μmol/L〕 | K〔M(P25,P75),μmol/L〕 | GLU〔M(P25,P75),μmol/L〕 | HbA1c〔M(P25,P75),g/L〕 | TyG Index〔M(P25,P75),mg/dL〕 | Fg 〔M(P25,P75),g/L〕 | |
非钙化组 | 2.26 (2.2,2.37) | 1.06(0.98,1.22) | 4.00(3.85,4.30) | 6.01(5.11,7.32) | 5.92(5.61,6.32) | 3.75(2.83,4.78) | 3.02(2.66,3.53) | |
低钙化指数组 | 2.28(2.22,2.39) | 1.13(0.98,1.28) | 4.10(3.80,4.40) | 6.42(5.13,8.14) | 6.32(5.91,7.41)a | 5.28(3.59,7.15)a | 2.91(2.62,3.61) | |
高钙化指数组 | 2.29(2.21,2.39) | 1.19(1.07,1.31)a | 4.01(3.71,4.32) | 6.61(5.22,8.51) | 6.22(5.91,7.52)a | 5.36(3.57,7.59)a | 3.11(2.56,3.61) | |
F(Z)值 | 0.513c | 1.772c | 0.659c | 1.256c | 1.114c | 2.216c | 0.704c | |
P值 | 0.577 | 0.005 | 0.357 | 0.520 | 0.012 | <0.001 | 0.948 |
因素 | B | SE | Wald χ2值 | P值 | OR值 | 95%CI |
---|---|---|---|---|---|---|
年龄 | 0.049 | 0.017 | 8.448 | 0.004 | 1.050 | (1.016,1.086) |
性别 | -0.004 | 0.450 | 0.001 | 0.993 | 0.996 | (0.412,2.407) |
吸烟史 | 0.508 | 0.358 | 2.016 | 0.156 | 1.662 | (0.824,3.351) |
糖尿病史 | -1.109 | 0.365 | 9.219 | 0.060 | 0.330 | (0.161,0.675) |
高血压史 | -0.525 | 0.329 | 2.548 | 0.110 | 0.591 | (0.310,1.127) |
甲状腺疾病史 | -1.190 | 0.834 | 2.035 | 0.154 | 0.304 | (0.059,1.561) |
TP | 0.036 | 0.040 | 0.782 | 0.377 | 1.036 | (0.957,1.122) |
ALP | 0.057 | 0.015 | 14.27 | 0.001 | 1.058 | (1.028,1.090) |
GGT | -0.007 | 0.015 | 0.192 | 0.661 | 0.933 | (0.964,1.024) |
A/G | -0.171 | 0.414 | 0.170 | 0.680 | 0.843 | (0.375,1.898) |
TyG Index | -0.030 | 0.126 | 0.057 | 0.811 | 0.970 | (0.758,1.241) |
TG | 2.074 | 0.461 | 20.240 | 0.001 | 7.958 | (3.224,19.640) |
HbA1c | 0.421 | 0.214 | 3.698 | 0.054 | 1.510 | (0.992,2.298) |
P | 2.151 | 0.894 | 5.789 | 0.016 | 8.596 | (1.490,49.590) |
Table 3 Multivariate Logistic regression analysis of influencing factors for coronary artery calcification
因素 | B | SE | Wald χ2值 | P值 | OR值 | 95%CI |
---|---|---|---|---|---|---|
年龄 | 0.049 | 0.017 | 8.448 | 0.004 | 1.050 | (1.016,1.086) |
性别 | -0.004 | 0.450 | 0.001 | 0.993 | 0.996 | (0.412,2.407) |
吸烟史 | 0.508 | 0.358 | 2.016 | 0.156 | 1.662 | (0.824,3.351) |
糖尿病史 | -1.109 | 0.365 | 9.219 | 0.060 | 0.330 | (0.161,0.675) |
高血压史 | -0.525 | 0.329 | 2.548 | 0.110 | 0.591 | (0.310,1.127) |
甲状腺疾病史 | -1.190 | 0.834 | 2.035 | 0.154 | 0.304 | (0.059,1.561) |
TP | 0.036 | 0.040 | 0.782 | 0.377 | 1.036 | (0.957,1.122) |
ALP | 0.057 | 0.015 | 14.27 | 0.001 | 1.058 | (1.028,1.090) |
GGT | -0.007 | 0.015 | 0.192 | 0.661 | 0.933 | (0.964,1.024) |
A/G | -0.171 | 0.414 | 0.170 | 0.680 | 0.843 | (0.375,1.898) |
TyG Index | -0.030 | 0.126 | 0.057 | 0.811 | 0.970 | (0.758,1.241) |
TG | 2.074 | 0.461 | 20.240 | 0.001 | 7.958 | (3.224,19.640) |
HbA1c | 0.421 | 0.214 | 3.698 | 0.054 | 1.510 | (0.992,2.298) |
P | 2.151 | 0.894 | 5.789 | 0.016 | 8.596 | (1.490,49.590) |
[1] |
|
[2] |
《冠状动脉钙化病变诊治中国专家共识》专家组. 冠状动脉钙化病变诊治中国专家共识(2021版)[J].中国介入心脏病学杂志,2021,29(9):251-259. DOI:10.3969/j.issn.1004-8812.2021.05.002.
|
[3] |
田芳,李浩,刘雪梅,等. 维持性血液透析患者血尿酸与冠脉钙化的相关性研究[J].中国中西医结合肾病杂志,2018,19(4):324-326. DOI:10.3969/j.issn.1009-587X.2018.04.015.
|
[4] |
徐洪繁. 他汀、脂蛋白(a)对冠状动脉钙化影响的横断面研究[D]. 大理: 大理大学,2021.
|
[5] |
黄鑫. 维持性血液透析患者冠状动脉钙化情况及相关因素分析[J]. 透析与人工器官,2021,32(3):17-18.
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
|
[11] |
|
[12] |
葛均波,王伟民,霍勇. 冠状动脉内旋磨术中国专家共识[J]. 中国介入心脏病学杂志,2017,25(2):61-66. DOI:10.3969/j.issn.1004-8812.2017.02.001.
|
[13] |
|
[14] |
|
[15] |
杨幼生,李姣. 血清ALP、MOTS-c水平在冠状动脉斑块稳定性中的价值分析[J]. 中国卫生标准管理,2022(3):70-74. DOI:10.3969/j.issn.1674-9316.2022.03.019.
|
[16] |
翟兰芳,李得娟. 血清ALP、musclin、cathepsin S水平与冠心病疾病严重程度的关系[J]. 中南医学科学杂志,2022,50(1):117-120. DOI:10.15972/j.cnki.43-1509/r.2022.01.028.
|
[17] |
Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin[J]. J Am Soc Nephrol,2004,15(6):1392-1401. DOI:10.1097/01.asn.0000128955.83129.9c.
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[22] |
|
[23] |
|
[24] |
|
[25] |
|
[26] |
|
[27] |
|
[28] |
|
[29] |
TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute,
|
[30] |
|
[31] |
范文俊,刘静怡,张英,等. 新型营养指数与稳定性冠心病及冠状动脉钙化斑块负荷的相关性[J]. 重庆医科大学学报,2022,47(1):74-79. DOI:10.13406/j.cnki.cyxb.002776.
|
[1] | ZHANG Aili, HOU Qiqi, HAN Quanle, ZHANG Boheng, ZHANG Jiawei, CAO Hongxia, ZHANG Chao, CHEN Shuohua, WU Shouling, LI Kangbo. Correlation between Atrial Fibrillation and the Risk of New-onset Chronic Kidney Disease in Northern Chinese Population [J]. Chinese General Practice, 2023, 26(36): 4521-4526. |
[2] | HU Chao, CHENG Xi, JIN Wangxun, YAO Hongqing, WANG Xinbao. Current Status of Lymphadenectomy during Radical Resection of Intrahepatic Cholangiocarcinoma: a Single-center Retrospective Study [J]. Chinese General Practice, 2023, 26(36): 4510-4513. |
[3] | TANG Can, LI Xiangyang, LI Jing, QIN Haoran, ZHU Hong. The Value of Nomogram Established by Serological Indicators and Tumor Diameter to Predict the Risk of Microvascular Invasion in Hepatocellular Carcinoma [J]. Chinese General Practice, 2023, 26(36): 4514-4520. |
[4] | LU Yihan, WANG Jiwen, SUN Yue, FENG Runrun, HAN Yufei, SONG Zhenzhen, SUN Ying, DAI Huihua, CHEN Xing. Risk Factors and Maternal and Neonatal Outcomes of Pregnant Women with Total Labor over 24 Hours [J]. Chinese General Practice, 2023, 26(35): 4459-4463. |
[5] | CHENG Hao, ZHOU Jinchi, LIU Xi, KANG Lin, FAN Ahui, DOU Weijia, LIU Zhenxiong. Risk Factors Analysis and Risk Prediction Model Establishment for Rebleeding Events within 3 Years after Endoscopic Treatment of Gastroesophageal Varices in Liver Cirrhosis Patients [J]. Chinese General Practice, 2023, 26(35): 4446-4452. |
[6] | LIU Weina, GE Haiyan, MA Jing, CAO Qinying, BAI Xingyu, CUI Shifang, QIAO Yanxia. A Study on the Relationship of Vitamin A and E Levels in Umbilical Cord Blood with Respiratory Distress Syndrome in Preterm Infants [J]. Chinese General Practice, 2023, 26(33): 4152-4158. |
[7] | LI Jixin, QIU Linjie, REN Yan, WANG Wenru, LI Meijie, ZHANG Jin. The Correlation of Dietary Inflammatory Index with Overweight, Obesity and Abdominal Obesity: a Meta-analysis [J]. Chinese General Practice, 2023, 26(32): 4089-4097. |
[8] | MA Liyuan, WANG Zengwu, FAN Jing, HU Shengshou. Interpretation of Report on Cardiovascular Health and Diseases in China 2022 [J]. Chinese General Practice, 2023, 26(32): 3975-3994. |
[9] | LI Yujing, JIN Yichao, CHEN Xing, JI Mengying, DAI Huihua. Risk Factors for Endometrial Lesions Detected by Hysteroscopy in Breast Cancer Patients Taking Tamoxifen [J]. Chinese General Practice, 2023, 26(32): 4026-4030. |
[10] | GAO Yang, WANG Yunxia, ZHANG You, GAO Chuanyu. Lipid Goal Attainment Rate and Influencing Factors in 45-year-old or Younger Acute Coronary Syndrome Patients with an Ultra-high Risk of Atherosclerotic Cardiovascular Disease after Lipid-lowering Treatment [J]. Chinese General Practice, 2023, 26(27): 3383-3387. |
[11] | SHEN Yu, CHEN Jian, SHOU Tiejun, YU Beirong. Characteristics of Unintentional Injuries in 15 773 Children [J]. Chinese General Practice, 2023, 26(26): 3282-3289. |
[12] | HE Manlan, YUAN Ping, HE Lei, CHEN Lu. Meta-analysis of Risk Factors for Urinary Tract Infection in Neurogenic Bladder [J]. Chinese General Practice, 2023, 26(21): 2659-2665. |
[13] | FENG Shuidong, LI Junyan, DENG Shuxiang, CHEN Limou, CAO Mengyue, TANG Yan, TANG Peng, LIU Jun, SHEN Minxue, YANG Fei. Association between Air Pollutant Exposure and Dyslipidemia in Middle-aged and Elderly People in Mining Areas [J]. Chinese General Practice, 2023, 26(18): 2238-2244. |
[14] | LYU Cuicui, WANG Qihua, XIAO Yao, JIANG Jing, LIU Xiaoyun. Impact of Elevated Fasting Blood Glucose on Urodynamic Parameters in Patients with Benign Prostatic Hyperplasia [J]. Chinese General Practice, 2023, 26(18): 2223-2226. |
[15] | XUE Jingru, SUN Suzhen. Clinical Characteristics and Risk Factors for Unfavourble Prognosis of Mycoplasma Pneumoniae Encephalitis in Children [J]. Chinese General Practice, 2023, 26(17): 2125-2131. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||